Among significant research news last week, US CNS specialist Axsome Therapeutics released new Phase III data on its recently ...

As required by law, Axsome and Hikma will submit the settlement agreement to the U.S. Federal Trade Commission and the U.S. Department of Justice for review. Similar patent litigation brought by ...

Axsome Therapeutics, Inc. (NASDAQ: AXSM) (Axsome), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders ...

Based on the feedback from the FDA, the Company’s regulatory data package would be sufficient for the submission of an sNDA for AXS-05 for the treatment of Alzheimer’s disease agitation. Axsome ...

We recently published an article titled Why These 15 Biotech Stocks Are Skyrocketing So Far In 2025. In this article, we are ...

In clinical developments, Axsome reported successful results from their EMERGE Phase 3 trial for SYMBRAVO, a migraine treatment, which showed substantial improvements over existing treatments.

Another major catalyst was the FDA approval of SYMBRAVO for the acute treatment of migraine with or without aura in adults. This was announced in early 2025. The company also has positive Phase 3 ...

Another major catalyst was the FDA approval of SYMBRAVO for the acute treatment of migraine with or without aura in adults. This was announced in early 2025. The company also has positive Phase 3 ...

The forward-looking statements include risks and uncertainties, including, but not limited to, the commercial success of the Company’s Sunosi®, Auvelity®, and Symbravo® products and the ...

SYMBRAVO demonstrated statistically significantly greater migraine treatment response compared to prior treatment with an oral CGRP inhibitor (p<0.001, mTOQ-4 total score, primary endpoint) 2-hour ...